<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770261</url>
  </required_header>
  <id_info>
    <org_study_id>DP-CTR208-III-03</org_study_id>
    <nct_id>NCT02770261</nct_id>
  </id_info>
  <brief_title>Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alvogen Korea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alvogen Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine superiority of DP-R208 compare to each monotherapy
      in patient with hypertension and primary hypercholesterolemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of mean seated Systolic Blood Pressure and Percent change of LDL cholesterol</measure>
    <time_frame>8weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Hypertension</condition>
  <condition>Cholesterolemia</condition>
  <arm_group>
    <arm_group_label>CR group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP-R208+Candesartan 32mg pla+Rosuvastatin 20mg pla</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CP group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DP-R208 pla+Candesartan 32mg+Rosuvastatin 20mg pla</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PR group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DP-R208 pla+Candesartan 32mg pla+Rosuvastatin 20mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DP-R208</intervention_name>
    <description>DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo</description>
    <arm_group_label>CR group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan32mg</intervention_name>
    <description>DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo</description>
    <arm_group_label>CP group</arm_group_label>
    <other_name>Candesartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg</intervention_name>
    <description>DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg</description>
    <arm_group_label>PR group</arm_group_label>
    <other_name>Rosuvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DP-R208 Placebo</intervention_name>
    <description>DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg</description>
    <arm_group_label>CP group</arm_group_label>
    <arm_group_label>PR group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan32mg Placebo</intervention_name>
    <description>DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg</description>
    <arm_group_label>CR group</arm_group_label>
    <arm_group_label>PR group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg Placebo</intervention_name>
    <description>DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo</description>
    <arm_group_label>CR group</arm_group_label>
    <arm_group_label>CP group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both man and woman who is over 19years old.

          -  Hypertension with primary cholesterolemia and satisfy the lab results that Mean msSBP
             is under 180mmHg and Mean msDBP is under 110mmHg and LDL-C is 250mg/DL or under and
             Triglycerides is under 400mg/dL

        Exclusion Criteria:

          -  Therapeutic lifestylechange is not enought during the study period

          -  SBP difference is bigger than 20mmHg or DBP difference is bigger than 10mmHg at
             screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changkyu Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <last_update_submitted>December 23, 2016</last_update_submitted>
  <last_update_submitted_qc>December 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DP-R208</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

